This site is intended for health professionals only!

Published on 1 March 2007

Share this story:

Recent advances in the treatment of myelodysplastic


Michel Delforge MD PhD
Assistant Professor of Haematology
Department of Haematology
University Hospital Leuven

The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal myeloid haemopathies with a complex underlying pathogenesis. MDS is a common haematological disorder that primarily affects the ageing population. Its clinical presentation is related to progressive bone marrow failure, but around 40% of the MDS population also has an increased risk for leukaemic transformation.(1,2) The International Prognostic

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: